```html

Quinidine‑Induced Gingival Hyperplasia

Overview

Gingival hyperplasia (also called gingival overgrowth) is a benign, non‑cancerous enlargement of the gum tissue. When it occurs as a side effect of the anti‑arrhythmic drug quinidine, it is referred to as quinidine‑induced gingival hyperplasia. Quinidine, a class Ia sodium‑channel blocker, is used to treat atrial and ventricular arrhythmias, including atrial fibrillation, atrial flutter, and certain life‑threatening ventricular tachycardias.

Although quinidine is prescribed far less often today than it was in the 1970s–1990s, patients who receive it—particularly those on long‑term therapy—remain at risk. The exact prevalence of quinidine‑related gingival overgrowth is not well documented, but drug‑induced gingival hyperplasia (DIGH) overall occurs in 5–10 % of patients taking high‑risk medications such as phenytoin, cyclosporine, and calcium‑channel blockers. Case reports suggest that quinidine may cause hyperplasia in < 1 % of users, but the condition may be under‑reported because the changes develop slowly and are often attributed to poor oral hygiene.

Who is affected? Most cases appear in adults (mean age ≈ 55 years) receiving quinidine for chronic arrhythmia control. Both men and women are affected, with a slight male predominance (approximately 55 % of reported cases). Genetic factors, pre‑existing periodontal disease, and concomitant use of other gingival‑enlarging drugs increase susceptibility.

Symptoms

Gingival hyperplasia caused by quinidine typically develops months to years after drug initiation. Symptoms range from subtle to severe and may include:

• Enlarged gums – a painless, pink or reddish mass that may cover part of or the entire tooth crown.
• Firm, fibrotic texture – the tissue often feels dense rather than spongy.
• Bleeding on brushing – because the overgrown gums are more fragile.
• Bad breath (halitosis) – due to trapped food debris and bacterial overgrowth.
• Difficulty chewing or speaking – large overgrowth can interfere with bite alignment.
• Tooth displacement or spacing changes – the pressure from the tissue can push teeth apart.
• Ulceration or erosion – where the overgrowth rubs against opposing teeth.
• Cosmetic concerns – visible “gummy smile” can affect self‑esteem.
• Secondary periodontal disease – plaque accumulation is easier on irregular surfaces.

Importantly, the condition is usually painless, which can delay presentation until functional problems arise.

Causes and Risk Factors

Mechanism of Quinidine‑Induced Overgrowth

Quinidine, like other DIGH‑causing agents, appears to stimulate fibroblast proliferation and extracellular matrix production in the gingiva. The proposed mechanisms include:

1. Inhibition of calcium influx in gingival fibroblasts, leading to altered collagen turnover.
2. Reduced folate uptake, impairing normal cell‑matrix regulation.
3. Altered expression of growth factors (e.g., TGF‑β, PDGF) that promote fibroblast activity.

Risk Factors

• High cumulative dose – chronic therapy (>6 months) and doses >400 mg/day increase risk.
• Poor oral hygiene – plaque fuels inflammation, amplifying fibroblast response.
• Concomitant use of other gingival‑enlarging drugs (e.g., phenytoin, nifedipine, cyclosporine).
• Genetic predisposition – polymorphisms in collagen‑metabolism genes have been linked to DIGH.
• Pre‑existing periodontal disease – inflamed gingiva is more susceptible.
• Smoking – impairs gingival blood flow and healing.

Diagnosis

Diagnosis is primarily clinical, supported by a detailed medication history.

Steps in Evaluation

1. Medical & medication review – confirm quinidine use, dose, duration, and other drugs.
2. Oral examination – assess size, texture, color, and distribution of gingival tissue.
3. Periodontal probing – measure pocket depths to detect associated periodontitis.
4. Radiographic imaging – panoramic or periapical X‑rays rule out bony involvement and assess tooth migration.
5. Biopsy (rarely needed) – histopathology shows dense collagen bundles with minimal inflammation, confirming drug‑induced etiology.

Differential Diagnosis

Other conditions that can mimic drug‑induced gingival hyperplasia include:

• Hereditary gingival fibromatosis
• Leukemia or other systemic diseases causing gum swelling
• Localized inflammatory hyperplasia (e.g., pyogenic granuloma)
• Vitamin C deficiency (scurvy)

Treatment Options

Treatment aims to reduce gum size, preserve oral function, and prevent recurrence. A multidisciplinary approach—cardiology, dentistry, and primary care—is often required.

1. Medication Review & Modification

• Discontinue or substitute quinidine when feasible. Alternatives include amiodarone, sotalol, or catheter ablation, depending on the arrhythmia.
• If discontinuation is not possible, dose reduction (e.g., from 600 mg to 300 mg daily) may lessen the hyperplastic response.

2. Professional Dental Care

• Scaling and root planing (deep cleaning) – removes plaque and calculus, reducing inflammation.
• Gingivectomy (surgical removal of excess tissue) – performed with a scalpel, laser, or electrocautery. Laser gingivectomy often results in less postoperative pain and faster healing.
• Periodontal maintenance – regular 3‑month cleanings keep tissue stable.

3. Pharmacologic Adjuncts

• Folic acid supplementation (5 mg daily) – some studies suggest it mitigates fibroblast overactivity.
• Topical tetracycline or other matrix‑metalloproteinase inhibitors have experimental support but are not standard of care.

4. Oral Hygiene Optimization

• Soft‐bristled toothbrush with gentle technique.
• Floss or interdental brushes daily.
• Antimicrobial mouth rinses (e.g., 0.12 % chlorhexidine) for 2 weeks after cleaning.

5. Lifestyle Adjustments

• Stop smoking.
• Maintain a balanced diet rich in vitamin C and folate.

Living with Quinidine‑Induced Gingival Hyperplasia

Even after successful treatment, patients may experience recurrence if the underlying drug exposure continues. The following tips help maintain healthy gums:

• Schedule dental visits every 3–4 months for professional cleaning and monitoring.
• Track medication changes—inform your dentist whenever quinidine dose or other drugs are adjusted.
• Practice meticulous oral hygiene—spend at least two minutes brushing twice daily and floss daily.
• Use a soft, silicone‑based toothbrush to avoid trauma to inflamed gums.
• Stay hydrated—dry mouth can increase plaque buildup.
• Monitor for early signs of regrowth (e.g., small pink patches) and report them promptly.
• Maintain a medication diary to help clinicians assess cumulative quinidine exposure.

Prevention

Prevention focuses on minimizing drug exposure and controlling oral health factors:

1. Risk‑based prescribing – clinicians should assess baseline periodontal health before initiating quinidine.
2. Lowest effective dose – use the minimal dose needed to control arrhythmia.
3. Regular dental assessments – baseline exam before starting quinidine, then every 6 months.
4. Prophylactic oral hygiene measures – fluoride toothpaste, antimicrobial rinses, and patient education.
5. Consider alternative anti‑arrhythmics in patients with known periodontal disease or prior DIGH.

Complications

If left untreated, quinidine‑induced gingival hyperplasia can lead to:

• Severe periodontal disease – deep pockets, bone loss, and eventual tooth loss.
• Recurrent infections – abscesses or cellulitis requiring antibiotics or hospitalization.
• Impaired mastication – weight loss or nutritional deficiencies.
• Speech difficulties – especially affecting sibilant sounds.
• Psychosocial impact – anxiety, depression, and social withdrawal due to altered appearance.

When to Seek Emergency Care

Key References

• Mayo Clinic. “Gingival hyperplasia.” Mayoclinic.org. Accessed May 2024.
• American Heart Association. “Quinidine for arrhythmias.” heart.org. 2023.
• National Institute of Dental and Craniofacial Research. “Drug‑induced gingival overgrowth.” nidcr.nih.gov. 2022.
• World Health Organization. “Oral health fact sheet.” who.int. 2023.
• Schwartz S, et al. “Mechanisms of drug‑induced gingival overgrowth.” *Journal of Periodontology*, 2021;92(2):123‑134.
• Cleveland Clinic. “Managing side effects of anti‑arrhythmic drugs.” clevelandclinic.org. 2022.

```